Health
Russia’s COVID-19 vaccine shows over 91% efficacy in phase 3 trial: Lancet study – The Tribune India
Findings based on analysis of data from nearly 20,000 participants; Sputnik V is a two-part vaccine that includes two adenovirus vectors
Moscow, February 2
Russia’s Sputnik V vaccine against COVID-19 has shown 91.6 per cent efficacy in the phase 3 trial without any serious side effects, according to an interim analysis of data published in The Lancet journal on Tuesday.
The findings are based on analysis of data from nearly 20,000 participants – three-quarters of whom received the two-dose regimen of the adenovirus-based vaccine, Gam-COVID-Vac, and one quarter received a placebo.
Serious adverse events or those requiring hospital…
-
General17 hours agoWe’ve all talked about potential economic consequences for Australia of Trump’s policies. Now they’re happening
-
General14 hours agoStephanie Scott’s murder caused a ‘seismic’ shock in Leeton, and the hurt remains
-
Noosa News24 hours agoBrisbane doctor jailed for trafficking ‘breathtaking amount’ of drugs
-
Noosa News17 hours ago’Lethal new opioids’ prompt Wide Bay pill testing call